WG
OVID icon

Winton Group’s Ovid Therapeutics OVID Stock Holding History

Winton Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,829
Closed -$38K – 1104
2021
Q4 		$38K Sell
11,829
-42,227
-78% -$145K ﹤0.01% 985
2021
Q3 		$182K Buy
+54,056
New +$197K 0.01% 1250
2019
Q4 		– Sell
-10,388
Closed -$34K – 1718
2019
Q3 		$34K Buy
+10,388
New +$23.6K ﹤0.01% 1503

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Winton Group's OVID Position: Q1 2022 in Review

Winton Group sold out of Ovid Therapeutics (OVID) in Q1 2022, closing a stake of 11,829 shares — an estimated $38K sold.

Winton Group first reported a position in OVID in Q3 2019 and held it in 3 quarters. The position peaked at $182K in Q3 2021. 62 funds tracked by Wall St. Rank hold OVID as of Q1 2022.

  • Winton Group reported no remaining Ovid Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Winton Group sold 11,829 Ovid Therapeutics shares in Q1 2022, an estimated $38K.
  • Winton Group first reported a position in Ovid Therapeutics in Q3 2019 and held it in 3 quarters.
  • Winton Group's Ovid Therapeutics position peaked at $182K in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2022.

Based on Winton Group's 13F filing for Q1 2022, filed 11 May 2022.